226 related articles for article (PubMed ID: 28606079)
1. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study.
Jakobsen M; Kolodziejczyk C; Klausen Fredslund E; Poulsen PB; Dybro L; Paaske Johnsen S
BMC Health Serv Res; 2017 Jun; 17(1):398. PubMed ID: 28606079
[TBL] [Abstract][Full Text] [Related]
2. Societal Costs of First-Incident Ischemic Stroke in Patients with Atrial Fibrillation-A Danish Nationwide Registry Study.
Jakobsen M; Kolodziejczyk C; Fredslund EK; Poulsen PB; Dybro L; Johnsen SP
Value Health; 2016 Jun; 19(4):413-8. PubMed ID: 27325333
[TBL] [Abstract][Full Text] [Related]
3. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
[TBL] [Abstract][Full Text] [Related]
4. Cost of illness of atrial fibrillation: a nationwide study of societal impact.
Johnsen SP; Dalby LW; Täckström T; Olsen J; Fraschke A
BMC Health Serv Res; 2017 Nov; 17(1):714. PubMed ID: 29126415
[TBL] [Abstract][Full Text] [Related]
5. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
7. Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study.
Gustafsson N; Poulsen PB; Stallknecht SE; Dybro L; Paaske Johnsen S
Eur Heart J Qual Care Clin Outcomes; 2020 Apr; 6(2):130-137. PubMed ID: 31287536
[TBL] [Abstract][Full Text] [Related]
8. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis.
Desbiens NA
J Am Geriatr Soc; 2002 May; 50(5):863-9. PubMed ID: 12028173
[TBL] [Abstract][Full Text] [Related]
9. Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.
Tawfik A; Wodchis WP; Pechlivanoglou P; Hoch J; Husereau D; Krahn M
Appl Health Econ Health Policy; 2016 Jun; 14(3):313-22. PubMed ID: 26924098
[TBL] [Abstract][Full Text] [Related]
10. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study.
Brønnum Nielsen P; Larsen TB; Gorst-Rasmussen A; Skjøth F; Rasmussen LH; Lip GYH
Chest; 2015 Jun; 147(6):1651-1658. PubMed ID: 25412369
[TBL] [Abstract][Full Text] [Related]
11. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
Leey JA; McCabe S; Koch JA; Miles TP
Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A; Stock S; Stollenwerk B; Müller D
Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L; Rosenqvist M; Lip GY
Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
[TBL] [Abstract][Full Text] [Related]
17. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.
Nielsen PB; Larsen TB; Skjøth F; Gorst-Rasmussen A; Rasmussen LH; Lip GY
Circulation; 2015 Aug; 132(6):517-25. PubMed ID: 26059010
[TBL] [Abstract][Full Text] [Related]
18. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
von Schéele B; Fernandez M; Hogue SL; Kwong WJ
Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study.
Björck S; Palaszewski B; Friberg L; Bergfeldt L
Stroke; 2013 Nov; 44(11):3103-8. PubMed ID: 23982711
[TBL] [Abstract][Full Text] [Related]
20. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
Masbah N; Macleod MJ
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
